Affiliation:
1. Centre for Medical Image Computing University College London London UK
2. Dementia Research Centre UCL Queen Square Institute of Neurology London UK
3. Donders Centre for Cognitive Neuroimaging Donders Institute for Brain Cognition and Behaviour Radboud University Nijmegen the Netherlands
4. Department of Cognitive Neuroscience Radboud University Medical Centre Nijmegen the Netherlands
5. Department of Radiology and Biomedical Imaging University of California San Francisco San Francisco California USA
6. Department of Clinical Sciences Lund University Malmö Sweden
Abstract
AbstractINTRODUCTIONNeuroanatomical normative modeling captures individual variability in Alzheimer's disease (AD). Here we used normative modeling to track individuals’ disease progression in people with mild cognitive impairment (MCI) and patients with AD.METHODSCortical and subcortical normative models were generated using healthy controls (n ≈ 58k). These models were used to calculate regional z scores in 3233 T1‐weighted magnetic resonance imaging time‐series scans from 1181 participants. Regions with z scores < –1.96 were classified as outliers mapped on the brain and summarized by total outlier count (tOC).RESULTStOC increased in AD and in people with MCI who converted to AD and also correlated with multiple non‐imaging markers. Moreover, a higher annual rate of change in tOC increased the risk of progression from MCI to AD. Brain outlier maps identified the hippocampus as having the highest rate of change.DISCUSSIONIndividual patients’ atrophy rates can be tracked by using regional outlier maps and tOC.Highlights
Neuroanatomical normative modeling was applied to serial Alzheimer's disease (AD) magnetic resonance imaging (MRI) data for the first time.
Deviation from the norm (outliers) of cortical thickness or brain volume was computed in 3233 scans.
The number of brain‐structure outliers increased over time in people with AD.
Patterns of change in outliers varied markedly between individual patients with AD.
People with mild cognitive impairment whose outliers increased over time had a higher risk of progression from AD.
Funder
National Institutes of Health
National Institute on Aging
National Institute of Biomedical Imaging and Bioengineering
AbbVie
Alzheimer's Association
Alzheimer's Drug Discovery Foundation
BioClinica
Biogen
Eisai Incorporated
Eli Lilly and Company
F. Hoffmann-La Roche
Genentech
Fujirebio Europe
GE Healthcare
H. Lundbeck A/S
Novartis Pharmaceuticals Corporation
Pfizer
Servier
Takeda Pharmaceutical Company
Canadian Institutes of Health Research
Northern California Institute for Research and Education
Foundation for the National Institutes of Health
University of Southern California
UCLH Biomedical Research Centre
Brain Research UK
Weston Brain Institute
Medical Research Council
British Heart Foundation
National Research, Development and Innovation Office
Alzheimer's Disease Neuroimaging Initiative
Agence Nationale de la Recherche